VERTEX PHARMACEUTICALS INC / MA 8-K

What Happened
Vertex Pharmaceuticals Incorporated (VRTX) filed a Form 8-K on February 12, 2026, announcing it issued a press release reporting its consolidated financial results for the three and twelve months ended December 31, 2025. The press release is attached to the 8-K as Exhibit 99.1.

Key Details

• Filing date: February 12, 2026 (Form 8-K, Item 2.02).
• Periods reported: consolidated results for the three months and the twelve months ended December 31, 2025.
• Exhibits: press release attached as Exhibit 99.1; Inline XBRL cover page included as Exhibit 104.
• Disclosure note: the press release (Exhibit 99.1) is furnished and is not deemed “filed” for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings, except by specific reference.

Why It Matters
This 8-K signals Vertex’s official quarterly and full-year earnings communication to investors — a primary source for revenue, profit, guidance changes, and other performance metrics that can affect the stock. Retail investors should review the attached press release and the company’s subsequent filings or investor materials for the detailed numbers (revenue, net income, EPS, guidance) and any commentary on business drivers or outlook.